en

/

sv

About Elicera

Elicera in brief Board Management Elicera's history

Immuno-oncology

What is immuno-oncology?
Oncolytic virus CAR T-cell therapy

Technology

Strengths ELC-001 ELC-100 ELC-201 ELC-301 ELC-401 Patents

Pipeline

Pipeline Clinical trials

Investors

Press Releases Articles of Association General Meeting Board Management the Share Financial Reports Financial Calendar Events

The Share

List of 10 largest shareholders in Elicera as of November 25th, 2020

Name

Shares

Capital/Votes, %

Magnus Essand

3 293 000

27,37

Di Yu

3 293 000

27,37

Jamal El-Mosleh

2 664 000

22,14

Cardeon Futuring Finance AB

715 200

5,94

VictoryNET-Foundation

576 800

4,79

John Fällström

357 600

2,97

Arne Grundström

178 800

1,49

Gerhard Dal

107 200

0,89

Agneta Edberg

100 000

0,83

Maria Zandi

89 400

0,74

Others

657 000

5,46

Total

12 032 000

100

Elicera Therapeutics AB is a clinical stage immuno-oncology company developing cell and gene therapies for immune-based cancer treatments.

Elicera Therapeutics AB (publ)
info@elicera.com
+46 (0)70-331 90 51‬